Trial Profile
The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Esomeprazole (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms The BIO-GIO study
- 01 Nov 2022 Primary endpoint (To evaluate the area under the curve of afatinib compared to afatinib concomitantly used with esomeprazole and to afatinib used with esomeprazole 3 hours prior in patients with non-small cell lung cancer.) has not been met, according to Results published in the Biomedicine and Pharmacotherapy.
- 01 Nov 2022 Results published in the Biomedicine and Pharmacotherapy
- 21 Jul 2017 New trial record